International Reference Pricing and Most Favored Nation Policies – Outlook and Impacts on Innovation
June 18, 2025
Super Session
Special Program
253ABC
On May 12, 2025, the Trump Administration announced a new Executive Order, “Delivering Most Favored Nation Prescription Drug Pricing to American Patients.” This was followed by an announcement on May 20, 2025, that the Department of Health and Human Services (HHS) expected manufacturers to align U.S. pricing with an “MFN target price” based on certain OECD countries. Panelists will discuss the implications of these announcements, what authorities the Trump Administration has to implement such approaches, and the impacts these policies will have on innovation and patient access to medicine.
Moderator
Senior Vice President, Health Policy & Research
Biotechnology Innovation Organization (BIO)
Speakers
.jpg)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}